Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Liquidia Corp. (LQDA)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$44.49-6.10%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
2.34 → 2.19 EPS · FY ending Dec 31, 2027 · 5 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for LQDA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operations | Cash from operations also rose, supporting growth. | Improving | Cash from operations falls below $40M in any quarter after 2026-Q1 | Cash from operations: $80.244M FY2026-Q2; GAAP. Published target: Cash from operations >= $50M quarterly. Target period is not explicitly aligned with this observation. Aug 12, 202680,244,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented healthcare business with a clinical development component, rather than a proven durable compounder. The long-term thesis is intact: sales, patient adoption, and profitability improved in the latest quarter, while L606 development is progressing but remains mixed.
LQDA is expensive versus peers, and the valuation model points to expectations running ahead of its fundamentals, though confidence in that model is low. The priced-in signal is marked justified, with no fragility gates triggered, but the premium leaves the thesis sensitive to weaker execution.
Near term, YUTREPIA sales and patient adoption have been growing, and net income and adjusted EBITDA increased from the first to the second quarter. Management’s sales and profitability priorities are on track, but the company remains classified as loss-making, and a recent quarterly miss and erratic earnings surprises keep execution risk elevated.
Over the next few quarters, the key test is whether YUTREPIA sales growth and profitability continue, and whether guidance avoids a cut. L606’s pivotal study is advancing, but its financial contribution is not established in the evidence; litigation is also a recent negative event. Healthcare sector momentum may help if bellwethers continue to report well, while weakening jobs data could raise recession concerns.
For the 1-3 year view, the business evidence is improving and the thesis remains intact, but expensive valuation, execution uncertainty, and recent litigation make the setup fragile to disappointing updates. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Net income improved from $15M to $53M, showing better profits. |
| Intact |
| Net income falls below $30M in any quarter after 2026-Q1 |
Net income: $74.722M FY2026-Q2; GAAP. Published target: Maintain net income >= $50M quarterly. Target period is not explicitly aligned with this observation. Aug 12, 202674,722,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Full year 2026 revenue | A primary condition in Liquidia Corp.'s published investment case. The stated target is Revenue >= $130M for full year 2026. | Broken | Full year 2026 revenue falls below $120M | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Product sales, net, were $170.4 million for the three months ended June 30, 2026, compared to $6.5 million for the three months ended June 30, 2025.” “Preliminary and unaudited results from the third quarter 2026 included YUTREPIA net product sales of $222.7 million, contributing to total cash and cash equivalents of $396.1 million as of September 30, 2026.” Delivery assessment Nov 4, 2026 |
YUTREPIA net product sales | Liquidia is growing sales of YUTREPIA fast, from $54M to $133M in recent quarters. | Intact | YUTREPIA sales fall below $100M in any quarter after 2026-Q1 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Product sales, net, were $170.4 million for the three months ended June 30, 2026, compared to $6.5 million for the three months ended June 30, 2025.” “Preliminary and unaudited results from the third quarter 2026 included YUTREPIA net product sales of $222.7 million, contributing to total cash and cash equivalents of $396.1 million as of September 30, 2026.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$5.70 → $2.19 · observed estimates
$1.18B → $0.76B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $5.70 | $1,184,371,864 | 5 / 5 |
| 2026-07-25 | $5.70 | $1,184,371,864 | 5 / 5 |
| 2026-07-26 | $5.70 | $1,184,371,864 | 5 / 5 |
| 2026-07-27 | $5.70 | $1,184,371,864 | 5 / 5 |
| 2026-07-28 | $5.81 | $1,184,247,290 | 5 / 7 |
| 2026-07-29 | $5.81 | $1,184,253,010 | 5 / 7 |
| 2026-07-30 | $5.81 | $1,184,253,010 | 5 / 7 |
| 2026-07-31 | $5.81 | $1,184,253,010 | 5 / 7 |
| 2026-08-01 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-02 | $5.81 | $1,184,253,010 | 5 / 7 |
| 2026-08-03 | $5.81 | $1,184,253,010 | 5 / 7 |
| 2026-08-04 | $5.81 | $1,184,253,010 | 5 / 7 |
| 2026-08-05 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-06 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-07 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-08 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-09 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-10 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-12 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-13 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-14 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-15 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-16 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-17 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-18 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-19 | $5.86 | $1,184,377,579 | 5 / 5 |
| 2026-08-20 | $5.57 | $1,225,751,571 | 5 / 5 |
| 2026-08-21 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-22 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-23 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-24 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-25 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-26 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-27 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-28 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-29 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-30 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-08-31 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-01 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-02 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-03 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-04 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-05 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-06 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-07 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-08 | $5.57 | $1,225,761,429 | 5 / 5 |
| 2026-09-09 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-10 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-11 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-12 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-13 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-14 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-15 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-16 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-17 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-18 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-19 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-20 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-21 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-22 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-23 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-24 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-25 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-26 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-27 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-28 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-29 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-09-30 | $5.57 | $1,225,894,429 | 5 / 5 |
| 2026-10-01 | $4.54 | $1,091,426,686 | 4 / 4 |
| 2026-10-02 | $2.68 | $803,631,400 | 5 / 5 |
| 2026-10-03 | $2.34 | $739,002,686 | 4 / 5 |
| 2026-10-04 | $2.34 | $739,002,686 | 5 / 5 |
| 2026-10-05 | $2.34 | $739,002,686 | 5 / 5 |
| 2026-10-06 | $2.34 | $739,002,686 | 5 / 5 |
| 2026-10-07 | $2.34 | $739,002,685 | 5 / 5 |
| 2026-10-08 | $2.34 | $739,002,685 | 5 / 5 |
| 2026-10-09 | $2.34 | $739,002,685 | 5 / 5 |
| 2026-10-10 | $2.34 | $739,002,685 | 5 / 5 |
| 2026-10-11 | $2.10 | $707,691,736 | 5 / 5 |
| 2026-10-12 | $2.10 | $707,691,736 | 5 / 5 |
| 2026-10-13 | $2.10 | $707,691,736 | 5 / 5 |
| 2026-10-14 | $2.10 | $707,691,736 | 5 / 5 |
| 2026-10-15 | $2.19 | $762,175,423 | 5 / 5 |
| 2026-10-16 | $2.19 | $762,175,423 | 5 / 5 |
| 2026-10-17 | $2.19 | $762,175,423 | 5 / 5 |
| 2026-10-18 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-19 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-20 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-21 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-22 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-23 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-24 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-25 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-26 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-27 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-28 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-29 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-30 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-10-31 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-11-01 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-11-02 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-11-03 | $2.19 | $762,177,752 | 5 / 5 |
| 2026-11-04 | $2.19 | $762,177,752 | 5 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 5 recorded
2 raises · 2 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.